PORTIA: tisagenlecleucel and pembrolizumab in R/R DLBCL

PORTIA: tisagenlecleucel and pembrolizumab in R/R DLBCL

PORTIA: tisa-cel in R/R DLBCLПодробнее

PORTIA: tisa-cel in R/R DLBCL

Possibilities for the use of pembrolizumab in lymphoma treatmentПодробнее

Possibilities for the use of pembrolizumab in lymphoma treatment

FDA Approval of Tisagenlecleucel in DLBCLПодробнее

FDA Approval of Tisagenlecleucel in DLBCL

Importance of Clinical Trials in LymphomaПодробнее

Importance of Clinical Trials in Lymphoma

Why Is Clinical Trial Participation Vital for Diffuse Large B-Cell Lymphoma Patients?Подробнее

Why Is Clinical Trial Participation Vital for Diffuse Large B-Cell Lymphoma Patients?

Phase I trial results for nivolumab and pembrolizumab in lymphoma and multiple myelomaПодробнее

Phase I trial results for nivolumab and pembrolizumab in lymphoma and multiple myeloma

Prof: Loretta Nastoupil - pembrolizumab and rituximab in R/R FLПодробнее

Prof: Loretta Nastoupil - pembrolizumab and rituximab in R/R FL

IACH Journal Club Real world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemiПодробнее

IACH Journal Club Real world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemi

The role of antiphospholipid antibodies in SCDПодробнее

The role of antiphospholipid antibodies in SCD

Elizabeth Brém, MD, UCI - CLL and LymphomaПодробнее

Elizabeth Brém, MD, UCI - CLL and Lymphoma

POLARIX Trial and Polatuzumab in Frontline Chemotherapy for DLBCL - 2024 Blood Cancer OncTalkПодробнее

POLARIX Trial and Polatuzumab in Frontline Chemotherapy for DLBCL - 2024 Blood Cancer OncTalk

Controversies surrounding the management and treatment of lymphomasПодробнее

Controversies surrounding the management and treatment of lymphomas

Session highlights: autoSCT in T-cell lymphoma, classification updates and fertility preservationПодробнее

Session highlights: autoSCT in T-cell lymphoma, classification updates and fertility preservation

LOTIS-9 trial design: loncastuximab tesirine plus rituximab in elderly patients with DLBCLПодробнее

LOTIS-9 trial design: loncastuximab tesirine plus rituximab in elderly patients with DLBCL

Updates on the use of bispecific antibodies in MCL & the need for more studies in this spaceПодробнее

Updates on the use of bispecific antibodies in MCL & the need for more studies in this space

Loncastuximab tesirine as a consolidation strategy post-CAR T-cell therapy in DLBCLПодробнее

Loncastuximab tesirine as a consolidation strategy post-CAR T-cell therapy in DLBCL

LOTIS-5: loncastuximab tesirine + rituximab for elderly patients with R/R DLBCLПодробнее

LOTIS-5: loncastuximab tesirine + rituximab for elderly patients with R/R DLBCL

Kristofer Prepelica, PhD Discusses Lymphoma ResearchПодробнее

Kristofer Prepelica, PhD Discusses Lymphoma Research